PCV7 Vaccination Decreased Invasive Pneumococcal Disease
Following the introduction of the 7-valent pneumococcal conjugate vaccine in Calgary, Canada, there was a significant decrease in the number of cases of invasive pneumococcal disease among both children and adults in the area, according to new results from the Calgary-Area Streptococcus pneumoniae Research (CASPER) study.
The study involved a prospective, population-based surveillance of all cases of invasive pneumococcal disease in the Calgary Health Region between January 1998 and December 2007.
The researchers collected demographic and clinical data; viable isolates were saved and serotyped. The results demonstrated a significant decrease in the number of cases of invasive pneumococcal disease beginning in 2002, which is when routine infant vaccination with the 7-valent pneumococcal conjugate vaccine began in the area.
During the 10-year period of the study, there were a total of 1,182 cases of invasive pneumococcal disease. The researchers compared results from before and after routine vaccination began.
These results demonstrated the incidence of invasive pneumococcal disease due to 7-valent pneumococcal conjugate vaccine serotypes decreased significantly by 86% among those aged 6 to 23 months, 59% among those aged 2 to 4 years, 38% among those aged 16 to 64 years, and 78% among those aged 65 to 84 years.